The members of the Pharmacy Examining Board are appointed by the Governor and confirmed by the Legislature to serve 4-year terms. The Board consists of 5 licensed pharmacist members and 2 public members.
U.S. Food and Drug Administration's lists of all currently approved interchangeable biological products.
The following examples of a Patient Consultation Sign required by changes to Phar 7.08(7), and Delivery Insert of a board-approved copy of information as required by changes to Phar 7.08(8), have been approved by the Board for implementation in concert with revisions to Phar 7 which become effective January 1, 2021.
On June 4, 2020, the Pharmacy Examining Board adopted revisions to Phar 7, relating to the practice of pharmacy. Changes to Phar 7 will become effective on January 1, 2021.
Phar 7: Practice of Pharmacy
Adoption Order (Outlines changes to rules adopted on June 4, 2020)
Please be advised that updates to the rule text in its official and final form will become available on the Legislative Reference Bureau site after the effect date of the adopted rule at this link:
The 2017 Quarter 4 ePDMP Report is now available.
2017 Quarter 4 e PDMP Report
Effective November 1, 2017, Phar 6 Has Been Updated Per 2017 Wisconsin Act 18
Phar 6 - Pharmacy Licenses and Equipment
2017 Wisconsin Act 18
Effective November 1, 2017, Phar 14 Has Been Updated
Phar 14 - Home Medical Oxygen Providers
Effective September 1, 2017, Phar 7.10 Has Been Updated
Phar 7.10 - Administration of drug products and devices other than vaccines
On October 1, 2016 the following Pharmacy Chapters were updated:
Phar 1, 8 Relating to Definitions and Controlled Substances
Phar 1, 2 and 4 Relating to Application and Examination
Phar 5 Relating to Renewal and Reinstatement
Phar 8 Relating to Identification Card Required for Certain Controlled Substances
2015 Act 313 went into effect on April 1, 2016. This Act no longer authorizes the Pharmacy Board to grant variances unless a disaster or emergency exists, but to instead institute
pilot projects. The Board is currently engaged in the transitioning of current non-emergency variances into pilot projects. Please see the link for more detailed information as to the Statutory requirements.
CSB 4.04(2)(p) goes into effect on April 9, 2017. This requires that the name recorded under
s. 450.11(1b)(bm), Stats. be submitted to the Prescription Drug Monitoring Program.
2015 Act 291 relating to prescription fills and refills went into effect on April 1, 2016.
Please review the following update:
NTSB Information on Risk of Pilot Impairment
As of September 1, 2014,
8.09 were amended to allow electronic prescriptions for schedule II controlled substances.
On August 28, 2014 the DEA published its final rule in the Federal Register placing Suvorexant into Schedule IV of the Federal Controlled Substances Act. The scheduling action was effective September 29, 2014. The Wisconsin Controlled Substances Board pursuant to s. 961.11(4), Stats took affirmative action to treat
Suvorexant as a Schedule IV effective November 1, 2014.
On August 22, 2014 the DEA published its final rule in the Federal Register rescheduling hydrocodone combination products from Schedule III to Schedule II of the Federal Controlled Substances Act. The scheduling action was effective October 6, 2014. The Wisconsin Controlled Substances Board pursuant to s. 961.11(4), Stats took affirmative action to similarly
reschedule hydrocodone combination products from Schedule III to Schedule II effective November 1, 2014.
On July 2, 2014, the DEA published its final rule in the Federal Register placing tramadol into schedule IV of the federal Controlled Substances Act effective August 18, 2014. The Wisconsin Controlled Substances Board pursuant to s. 961.11(4), Stats took affirmative action to similarly treat tramadol as a
schedule IV controlled substance effective September 1, 2014.
As of November 1, 2013,
Phar 7.01(1)(e), Wis. Admin. Code, relating to delivery, became effective.
Last updated: 1/3/2022